Skip to main content

Table 1 Baseline characteristics by the most frequent opioid use route and maintenance dosage groups

From: Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder

Maintenance dose groups

Opioid-injecting participants

Non-injecting opioid participants

BUP-XR 300/300 mg

BUP XR 300/100 mg

Total

BUP-XR 300/300 mg

BUP-XR 300/100 mg

Total

(N = 63)

(N = 66)

(N = 129)

(N = 92)

(N = 90)

(N = 182)

Category

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

Age (Years):

39.6

40.3

39.9

40.1

41.7

40.9

Mean (SD)

(11.28)

(11.75)

(11.48)

(10.92)

(10.49)

(10.71)

Age group (Years)

≥ 18 to < 30

14 (22.2)

13 (19.7)

27 (20.9)

18 (19.6)

15 (16.7)

33 (18.1)

≥ 30 to < 45

28 (44.4)

28 (42.4)

56 (43.4)

43 (46.7)

38 (42.2)

81 (44.5)

≥ 45 to < 60

18 (28.6)

21 (31.8)

39 (30.2)

28 (30.4)

35 (38.9)

63 (34.6)

≥ 60

3 (4.8)

4 (6.1)

7 (5.4)

3 (3.3)

2 (2.2)

5 (2.7)

Gender: Male

46 (73.0)

40 (60.6)

86 (66.7)

57 (62.0)

59 (65.6)

116 (63.7)

Race

White

50 (79.4)

43 (65.2)

93 (72.1)

57 (62.0)

58 (64.4)

115 (63.2)

Black or African-American

13 (20.6)

20 (30.3)

33 (25.6)

33 (35.9)

30 (33.3)

63 (34.6)

Ethnicity: Hispanic or Latino

9 (14.3)

6 (9.1)

15 (11.6)

3 (3.3)

2 (2.2)

5 (2.7)

Tobacco use status at screen

Current

60 (95.2)

57 (86.4)

117 (90.7)

74 (80.4)

77 (85.6)

151 (83.0)

Former

2 (3.2)

4 (6.1)

6 (4.7)

7 (7.6)

5 (5.6)

12 (6.6)

Never

1 (1.6)

5 (7.6)

6 (4.7)

11 (12.0)

8 (8.9)

19 (10.4)

Alcohol use status at screen

Current

33 (52.4)

34 (51.5)

67 (51.9)

53 (57.6)

47 (52.2)

100 (54.9)

Former

21 (33.3)

17 (25.8)

38 (29.5)

18 (19.6)

23 (25.6)

41 (22.5)

Never

9 (14.3)

15 (22.7)

24 (18.6)

21 (22.8)

20 (22.2)

41 (22.5)

Opioid use disorder severitya

Moderate

15 (22.7)

19 (30.2)

34 (26.4)

25 (28.1)

32 (35.2)

57 (31.7)

Severe

51 (77.3)

44 (69.8)

95 (73.6)

64 (71.9)

59 (64.8)

123 (68.3)

Missing

   

1

1

2

Daily opioid use in past 30 days (Yes vs. No)

Yes

51 (81.0)

55 (83.3)

106 (82.2)

76 (82.6)

73 (81.1)

149 (81.9)

No

12 (19.0)

11 (16.7)

23 (17.8)

16 (17.4)

17 (18.9)

33 (18.1)

Last buprenorphine dose before BUP-XR/placebo injection (mg)

Mean (SD)

15.0 (4.92)

15.5 (5.39)

15.3 (5.15)

15.7 (6.06)

15.9 (4.67)

15.8 (5.41)

Median

16.0

16.0

16.0

16.0

16.0

16.0

Max, Min

8, 24

8, 24

8, 24

8, 48

8, 24

8, 48

Q1, Q3

10, 20

12, 20

12, 20

12, 20

12, 20

12, 20

Lifetime opioid use (Year):

12.1

13.4

12.8

11.2

11.7

11.5

Mean (SD)

(9.27)

(12.16)

(10.82)

(9.27)

(8.84)

(9.04)

Cocaine use history or use at screenb

37 (58.7)

46 (69.7)

83 (64.3)

37 (40.2)

44 (48.9)

81 (44.5)

Polydrug use history or use at screenc

50 (79.4)

57 (86.4)

107 (82.9)

62 (67.4)

73 (81.1)

135 (74.2)

Preexisting psychiatric disorder

20 (31.7)

12 (18.2)

32 (24.8)

20 (21.7)

19 (21.1)

39 (21.4)

Employed at screen

22 (34.9)

16 (24.2)

38 (29.5)

39 (42.4)

35 (38.9)

74 (40.7)

  1. Shown for the efficacy analysis set (participants who received at least one maintenance dose (BUP-XR 300 mg vs. 100 mg). Q, quartile; SD, standard deviation; UDS, urine drug screen
  2. aBased on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria [35]
  3. bSelf-reported cocaine use history or self-reported cocaine use within one week prior to screen or UDS-detected cocaine use at screen visit
  4. cSelf-reported polydrug use history or UDS-detected Meth/amphetamine, cocaine metabolites, benzodiazepines, cannabinoids, or phencyclidine use at screen visit
Back to article page

Harm Reduction Journal

ISSN: 1477-7517